Genomics Flashcards Preview

PK/PD > Genomics > Flashcards

Flashcards in Genomics Deck (33):
1

amitryptyline metabolism pathway

2C19 activates it
2D6 deactivates

2

2D6 genotypes

-normal = 1, 2
-non-functional = 3-8

3

amitryptyline 2C19 recommendations

-avoid in ultrarapid and poor metabolizers
-standard dose in extensive and intermediate

4

amitryptyline 2D6 recommendations

-avoid in ultrarapid and poor
-25% reduction in intermediate

5

simvastatin gene involved in metabolism

SLCO1B1

6

simvastatin genotypes/phenotypes

-TT = standard
-TC = intermediate
-CC = low function

7

simvastatin dosing recommendations

-TT = normal
-TC = lower dose or alternative
-CC = lower dose or alternative

8

methotrexate metabolism by

SLC19A1

9

methotrexate mutation

SNP at SLC19A1

10

methotrexate recommendations

no definitive recommendations
-higher risk of toxicity has been seen

11

clopidogrel metabolism

2C19

12

clopidogrel phenotypes

-Ultra = 17
-extensive = 1/1
-intermediate = 1 and 2-8 or 17 and 2-8
-poor = 2-8

13

clopidogrel recommendations

any loss of function allele should get alternative therapy
-still use in ultra rapid

14

bupropion metabolised by

2B6

15

bupropion moderately inhibits

2D6

16

gene related to smoking cessation in bupropion

ANKK1

17

bupropion recommendations

-loss of 2B6 may need other treatment
-ANKK1 AA or AG may have decreased response

18

codeine metabolism

2D6

19

codeine recommendations

-alternative in ultra rapid and poor

20

aripiprazole metabolism

3A4
2D6

21

aripiprazole recommendations

-poor 2D6 = reduce dose by half
-poor 2D6 + 3A4 inhib = reduce to 1/4

22

drugs to do HLA-B*5701 test for

abacavir
carbamazepine

23

patients to do HLA testing when using allopurinol

chinese

24

warfarin metabolism

VKORC
2C9

25

normal VKORC1 genotypes

G
C

26

VKORC1 mutations

G > A
C > T

27

2C9 genotypes

1 - normal
2,3 - reduced

28

warfarin recommendations

no specific, maybe use table

29

irinotecan mutation

UGT1A1*28

30

irinotecan recommendations

if UGT1A1*28 is present reduce dose by 30%

31

tamoxifen metabolism

*mainly activated 2D6*
some 2C9 and 3A4

32

tamoxifen recommendations

-avoid in poor
-consider something else in intermediate
-ultra rapid is fine

33

gene of interest in cetuximab and panitumumab

KRAS
if its not present then they won't work